ライフサイエンスコーパス: guanylyl

1 -(beta,gamma)-imidotriphosphate) or GMP-PCP (guanylyl 5'-(beta,gamma)-methylenediphosphonate) nor GDP

2 ured by agonist-stimulated [(35)S]GTPgammaS (guanylyl-5'-[O-thio]-triphosphate) binding) in both cell

3 structure for Cdc42 bound to the GTP analog guanylyl beta,gamma-methylene-diphosphonate (GMP-PCP) (i

4 Guanylyl cyclase (1H-(1,2,4)-oxadiazolo[4,3-a]-quinoxali

5 UCY1A3 encodes the alpha1 subunit of soluble guanylyl cyclase (alpha1-sGC), and CCT7 encodes CCTeta,

6 ginine methyl ester) and blockade of soluble guanylyl cyclase (by ODQ; 1H-1,2,4-oxadiazolo[4,3-a]quin

7 AY-41-2272 converts the CO adduct of soluble guanylyl cyclase (CO-sGC) enzyme from a low- to high-out

8 PSM2), RAP1GAP, and Gbeta5; cGMP modulators: guanylyl cyclase (GC) 1alpha1, GC1beta1, phosphodiestera

9 hat is lost when the predicted PEPR receptor guanylyl cyclase (GC) active site is mutated.

10 pr1 promoter activity and greatly stimulated guanylyl cyclase (GC) activity of the receptor protein i

11 activation of the intestinal receptor-enzyme guanylyl cyclase (GC) C, triggers an acute, watery diarr

12 Phosphodiesterase (PDE) and guanylyl cyclase (GC) enzymes are key components of the

13 RhoGC is a rhodopsin (Rho)-guanylyl cyclase (GC) gene fusion molecule that is centr

14 Soluble guanylyl cyclase (GC) is a heterodimer that is activated

15 and MyD88-dependent recruitment of platelet guanylyl cyclase (GC) toward the plasma membrane, follow

16 MP-receptive mechanisms and the inhibitor of guanylyl cyclase (GC), LY-83,583, on sleep in rats.

17 eptides and ATP activate and Go6976 inhibits guanylyl cyclase (GC)-A and GC-B.

18 hosphorylation is required for activation of guanylyl cyclase (GC)-A, also known as NPR-A or NPR1, by

19 gical effects in cells largely by activating guanylyl cyclase (GC)-coupled receptors, leading to cGMP

20 of cGMP from its receptor, the NO-sensitive guanylyl cyclase (GC1).

21 inct set of four known chemoreceptors of the guanylyl cyclase (gcy) gene family.

22 MCs) by acting on its receptor, NO-sensitive guanylyl cyclase (NO-GC).

23 the application of a nitric oxide-sensitive guanylyl cyclase (NO-sGC) receptor antagonist, a NOS inh

24 Retinal membrane guanylyl cyclase (RetGC) and Ca(2+)/Mg(2+) sensor protei

25 hat change the Ca(2+) sensitivity of retinal guanylyl cyclase (retGC) can result from an increase in

26 al for normal expression of retinal membrane guanylyl cyclase (RetGC) in photoreceptor cells, blocks

27 is an EF-hand protein that activates retinal guanylyl cyclase (RetGC) in photoreceptors at low free C

28 (2+) sensor protein that accelerates retinal guanylyl cyclase (RetGC) in the light and decelerates it

29 depend on Ca(2+)-regulated retinal membrane guanylyl cyclase (RetGC), comprised of two isozymes, Ret

30 Retinal guanylyl cyclase (RetGC)-activating proteins (GCAPs) reg

31 d Ca(2+) sensor in vision, regulates retinal guanylyl cyclase (RetGC).

32 hodiesterase (PDE6) or regulation of retinal guanylyl cyclase (retGC).

33 The GUCY2D gene encodes retinal membrane guanylyl cyclase (RetGC1), a key component of the photot

34 utations in the AFD-expressed gcy-8 receptor guanylyl cyclase (rGC) gene result in defects in the exe

35 onstrate the effect of NO donors and soluble guanylyl cyclase (sGC) activators in differentiation of

36 tives have been studied as potential soluble guanylyl cyclase (sGC) activators.

37 ivatives and tested their effects on soluble guanylyl cyclase (sGC) activity.

38 es that the functional properties of soluble guanylyl cyclase (sGC) are affected not only by the bind

39 dentified the alpha1-subunit gene of soluble guanylyl cyclase (sGC) as a novel androgen-regulated gen

40 nsertion is key during maturation of soluble guanylyl cyclase (sGC) because it enables sGC to recogni

41 es with the oxidation of the heme of soluble guanylyl cyclase (sGC) critically implicated in some of

42 Although soluble guanylyl cyclase (sGC) functions in an environment in wh

43 nine (NMMA); 300 or 500 microM) or a soluble guanylyl cyclase (sGC) inhibitor (1H-[1,2,4]oxadiazolo[4

44 ell volume that was abolished by the soluble guanylyl cyclase (sGC) inhibitor 1H-[1,2,4]oxadiazolo[4,

45 -arginine methyl ester; 30 mg/kg), a soluble guanylyl cyclase (sGC) inhibitor [1H-(1, 2, 4) oxadiazol

46 either a nitric oxide scavenger or a soluble guanylyl cyclase (sGC) inhibitor diminished the benefici

47 Diatomic ligand discrimination by soluble guanylyl cyclase (sGC) is paramount to cardiovascular ho

48 Soluble guanylyl cyclase (sGC) is the principal receptor for NO

49 Soluble guanylyl cyclase (sGC) is the receptor for nitric oxide

50 MP levels in this pathway, including soluble guanylyl cyclase (sGC) itself, the NO -activated form of

51 and cGMP in the above effects using soluble guanylyl cyclase (sGC) or adenylate cyclase (AC) specifi

52 Soluble guanylyl cyclase (sGC) plays an important role in cardio

53 d neuronal systems via activation of soluble guanylyl cyclase (sGC), a heme-containing heterodimer.

54 ch encodes the alpha1 subunit of the soluble guanylyl cyclase (sGC), a key enzyme in the nitric oxide

55 They were tested for activation of soluble guanylyl cyclase (sGC), a key enzyme in the NO/cGMP sign

56 Soluble guanylyl cyclase (sGC), a key protein in the NO/cGMP sig

57 nal nitric oxide synthase (nNOS) and soluble guanylyl cyclase (sGC), and can be mimicked by the nitri

58 the major downstream effector of NO, soluble guanylyl cyclase (sGC), in the superficial dorsal horn o

59 the major downstream effector of NO, soluble guanylyl cyclase (sGC), is very limited.

60 the major downstream effector of NO, soluble guanylyl cyclase (sGC), is very limited.

61 through activation of its receptor, soluble guanylyl cyclase (sGC), leading to elevation of intracel

62 presence of inhibitors selective for soluble guanylyl cyclase (sGC), PKG, calmodulin, CaMKII or ERK1/

63 ural homology to the beta subunit of soluble guanylyl cyclase (sGC), suggesting a NO sensing function

64 homologous to the central region in soluble guanylyl cyclase (sGC), the main receptor for nitric oxi

65 ular mechanism of desensitization of soluble guanylyl cyclase (sGC), the NO receptor, has long remain

66 ly vasoactive through stimulation of soluble guanylyl cyclase (sGC), which produces the second messen

67 tivating its intracellular receptor, soluble guanylyl cyclase (sGC).

68 light source, to activate the enzyme soluble guanylyl cyclase (sGC).

69 organic nitrate to the activation of soluble guanylyl cyclase (sGC).

70 organic nitrate to the activation of soluble guanylyl cyclase (sGC).

71 We compared the NO/soluble guanylyl cyclase (sGC)/cGMP pathway in human glioma tiss

72 ed the role of the nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cGMP/cGMP-dependent protein kinas

73 tes a pool of oxidized and heme-free soluble guanylyl cyclase (sGC; see the related article beginning

74 Although soluble guanylyl cyclase (which generates cyclic guanosine monop

75 s (GCAPs) bind and regulate retinal membrane guanylyl cyclase 1 (RetGC1) but not natriuretic peptide

76 erization domain of a human retinal membrane guanylyl cyclase 1 (RetGC1) linked to autosomal dominant

77 Retinal membrane guanylyl cyclase 1 (RetGC1) regulated by guanylyl cyclas

78 nfers Ca(2+)-sensitive activation of retinal guanylyl cyclase 1 (RetGC1).

79 Guanylyl cyclase 2C (GUCY2C) is a marker expressed by co

80 In intestinal epithelial cells, guanylyl cyclase 2C (GUCY2C) is a transmembrane receptor

81 o uroguanylin in the CNS, which can activate guanylyl cyclase 2C (GUCY2C) receptors in the brain to r

82 ic actions, as the endogenous ligand for the guanylyl cyclase 2C receptor has revealed a new system i

83 B-type natriuretic peptide (BNP) is a guanylyl cyclase A (GC-A) agonist.

84 effects were blocked by inhibition of either guanylyl cyclase A receptor or cyclic guanosine monophos

85 Inhibition of the soluble guanylyl cyclase abolished the effect of L-arginine on g

86 Guanylyl cyclase activating protein 1 (GCAP-1), a Ca(2+)

87 Guanylyl cyclase activating protein 1 (GCAP1), a member

88 Guanylyl cyclase activating protein 1 (GCAP1), after sub

89 Two calcium-sensitive guanylyl cyclase activating proteins (GCAP1 and GCAP2) a

90 and cone photoreceptors by calcium-sensitive guanylyl cyclase activating proteins (GCAP1 and GCAP2) i

91 activity is modulated by the calcium-binding guanylyl cyclase activating proteins (GCAP1 and GCAP2).

92 etGC1 and RetGC2 isozymes using mice lacking guanylyl cyclase activating proteins GCAP1 and GCAP2 and

93 icial effects of both nitric oxide-sensitive guanylyl cyclase activation and inhibition of the cGMP-d

94 ing, leading to NO production and subsequent guanylyl cyclase activation and K(ATP) channel opening i

95 al NMDARs and NOS stimulation and subsequent guanylyl cyclase activation that probably occurred in pe

96 important role in NO generation and soluble guanylyl cyclase activation under hypoxic conditions, wi

97 With the addition of nitrite, soluble guanylyl cyclase activation was significantly higher in

98 n but are well-tuned to the dynamic range of guanylyl cyclase activation.

99 tors (VPAC2 and NPR-C), inhibit adenylyl and guanylyl cyclase activities, and stimulate cAMP-specific

100 uced dephosphorylation of NPR2 decreases its guanylyl cyclase activity in growth plate chondrocytes i

101 y changes, but the absence of GCAP2 affected guanylyl cyclase activity in two ways; (a) the maximal r

102 mouse GCAP2 produced similar effects on the guanylyl cyclase activity in wild type retinas.

103 The guanylyl cyclase activity is modulated by the calcium-bi

104 xposed to green light, whereas inhibition of guanylyl cyclase activity negatively affects fungal phot

105 n kinase Ialpha on the phosphate content and guanylyl cyclase activity of NPR-A.

106 in 20 min, LH treatment results in decreased guanylyl cyclase activity of NPR2, as determined in the

107 Therefore, GCAP2 regulation of guanylyl cyclase activity quickens the recovery of flash

108 y Ca(2+)-dependent binding of recoverin, (2) guanylyl cyclase activity via Ca(2+)-dependent GCAP prot

109 CAP1 and GCAP2, confer Ca(2+) sensitivity to guanylyl cyclase activity, but the importance and the co

110 The protein exhibits robust light-dependent guanylyl cyclase activity, whereas a truncated form lack

111 eta1-sGC protein content, and impair soluble guanylyl cyclase activity.

112 oso-N-acetyl-DL-penicillamine) and a soluble guanylyl cyclase agonist (YC-1) mimicked AMPA effect in

113 Although guanylyl cyclase and downstream cGMP are essential regul

114 Dual stimulation of soluble guanylyl cyclase and inhibition of PDE5 activities also

115 signaling, was also inhibited by the soluble guanylyl cyclase and KATP channel blockers.

116 of injured aorta and in vitro by activating guanylyl cyclase and p38 MAPK.

117 imulatory role of NOS is mediated by soluble guanylyl cyclase and results from a cGMP-dependent stimu

118 cAMP receptor protein (CRP) is linked to the guanylyl cyclase and when deleted is deficient in cyst d

119 Nitric oxide (NO) stimulates soluble guanylyl cyclase and, thus, enhances cyclic guanosine mo

120 C-type natriuretic peptide activation of guanylyl cyclase B (GC-B), also known as natriuretic pep

121 ceptor for C-type natriuretic peptide (CNP), guanylyl cyclase B (GC-B, also known as Npr2 or NPR-B),

122 tor 3 and inactivating mutations in the NPR2 guanylyl cyclase both cause severe short stature, but ho

123 Blockade of soluble guanylyl cyclase by ODQ (1H-[1,2,4] oxadiazolo[4,3,-a]qu

124 Guanylyl cyclase C (GC-C) has been shown to be the prima

125 Guanylyl cyclase C (GC-C) is a multidomain, membrane-ass

126 Guanylyl cyclase C (GC-C) is expressed in intestinal epi

127 Guanylyl cyclase C (GC-C), an intestine-specific tumor s

128 Guanylyl cyclase C (GC-C), the receptor for diarrheageni

129 rgeting the intestinal cancer mucosa antigen guanylyl cyclase C (GCC) and its effect on inflammatory

130 tems, and the bacterial enterotoxin receptor guanylyl cyclase C (GCC), the principle source of cGMP i

131 ic tumors all express a unique surface-bound guanylyl cyclase C (GCC), which binds the diarrheagenic

132 ylin and uroguanylin, endogenous ligands for guanylyl cyclase C (GCC).

133 nuation of the colonic cell surface receptor guanylyl cyclase C (GUCY2C) that occurs due to loss of i

134 Guanylyl cyclase C (GUCY2C), a membrane-bound guanylyl c

135 enovirus (Ad5) combination regimen targeting guanylyl cyclase C (GUCY2C), a receptor expressed by int

136 endogenous ligands for the tumor suppressor guanylyl cyclase C (GUCY2C), disrupting a network of hom

137 Conversely, activating guanylyl cyclase C in human colon cancer cells delayed c

138 prior to defining the baseline expression of guanylyl cyclase C mRNA, a marker for colorectal cancer,

139 of a type I (microbial) rhodopsin domain and guanylyl cyclase catalytic domain.

140 cretes cGMP when developing cysts and that a guanylyl cyclase deletion strain fails to synthesize cGM

141 levation of cGMP after activation of soluble guanylyl cyclase does not relax the muscle.

142 ion of the cyclase activity, we isolated the guanylyl cyclase domain from Escherichia coli with (GCwC

143 , combining a type I rhodopsin domain with a guanylyl cyclase domain.

144 uanylyl cyclase C (GUCY2C), a membrane-bound guanylyl cyclase expressed in intestinal epithelial cell

145 segment of a natriuretic peptide receptor A guanylyl cyclase failed to bind GCAPs, but replacing its

146 nsory neurons (OSNs) expressing the receptor guanylyl cyclase GC-D, the cyclic nucleotide-gated chann

147 After stimulation with nitric oxide, soluble guanylyl cyclase generates cGMP, which induces vasodilat

148 s alters expression of AFD-specific receptor guanylyl cyclase genes.

149 We find that the Drosophila receptor guanylyl cyclase Gyc76C genetically interacts with Semap

150 on by the ligand NPPC, NPR2, the predominant guanylyl cyclase in follicular somatic cells, produces c

151 nated BlgC, was found to have photoactivated guanylyl cyclase in vitro.

152 induced airway relaxation was resistant to a guanylyl cyclase inhibitor (ODQ) and a protein kinase G

153 ine dihydrochloride (1400W) and the specific guanylyl cyclase inhibitor 1-H (1, 2, 4)oxadiazolo[4,3-a

154 -nitro-L-arginine methyl ester (L-NAME), the guanylyl cyclase inhibitor 1H- [1,2,4]oxadiazolo[4,3-a]q

155 Porcine leaflets exposed to the soluble guanylyl cyclase inhibitor ODQ increased osteocalcin and

156 mediated depolarizations were blocked by the guanylyl cyclase inhibitor ODQ indicating involvement of

157 nt with either a Ca(2+) channel blocker or a guanylyl cyclase inhibitor.

158 In addition to L-NAME, the guanylyl cyclase inhibitors ODQ and thrombospondin-1 als

159 Ps(-/-)) rods, indicating that regulation of guanylyl cyclase is not necessary for at least a part of

160 In cones, calcium feedback to guanylyl cyclase is potentially a key step in phototrans

161 lation of cGMP synthesis by retinal membrane guanylyl cyclase isozymes (RetGC1 and RetGC2) in rod and

162 nthesis in photoreceptor by retinal membrane guanylyl cyclase isozymes (RetGC1 and RetGC2) to expedit

163 ice that lack NO-GC specifically in SMCs (SM-guanylyl cyclase knockout [GCKO]), ICCs (ICC-GCKO), or b

164 in the granulosa cells by the transmembrane guanylyl cyclase natriuretic peptide receptor 2 (NPR2) i

165 natriuretic peptide (CNP), its receptor, the guanylyl cyclase natriuretic peptide receptor 2 (Npr2),

166 granulosa cells, where it is produced by the guanylyl cyclase natriuretic peptide receptor 2 (NPR2).

167 ow that one of these molecules, the receptor guanylyl cyclase Npr2, is required for bifurcation of th

168 hermore, inhibition of the NO target soluble guanylyl cyclase or of the cGMP effector kinase protein

169 Inhibitors of soluble guanylyl cyclase or PKG decreased activity of the I425V

170 n suppressing Foxp3(+) Tregs via the soluble guanylyl cyclase pathway.

171 luding the insulin, TGF-beta, serotonin, and guanylyl cyclase pathways; however, the sensory processe

172 nic mutation carriers contained less soluble guanylyl cyclase protein and consequently displayed redu

173 dly hypotensive and functions via a separate guanylyl cyclase receptor compared with CNP.

174 se (eNOS) by directly activating its soluble guanylyl cyclase receptor, rescued blood vessel function

175 s, evolutionary diversification of primitive guanylyl cyclase signaling pathways allows GUCY2C to coo

176 chieved by activating the endogenous soluble guanylyl cyclase that produces cGMP.

177 at this toxin is a dual soluble adenylyl and guanylyl cyclase that results in intracellular cAMP and

178 olar concentrations of nitric oxide activate guanylyl cyclase to produce cGMP, which has diverse phys

179 its receptor on the intestinal brush border, guanylyl cyclase type C (GC-C).

180 An inhibitor of soluble guanylyl cyclase, (1)H-(1,2,4)oxadiazolo(4,3-a)quinoxali

181 es an effector domain such as an adenylyl or guanylyl cyclase, all encoded in a single protein as a t

182 porters, nitric oxide (NO) synthase, soluble guanylyl cyclase, and ATP-sensitive potassium (KATP) cha

183 cked by inhibitors of nitric oxide synthase, guanylyl cyclase, and calcium/calmodulin.

184 phosphorylation and inactivation of the NPR2 guanylyl cyclase, and cGMP hydrolysis is increased by ac

185 ing pathway involving nitric oxide synthase, guanylyl cyclase, and cGMP-dependent protein kinase (PKG

186 e roles of endothelium-derived vasodilators, guanylyl cyclase, and potassium channels were examined i

187 3-kinase, endothelial nitric oxide synthase, guanylyl cyclase, and protein kinase G (PKG).

188 gether with Ca(2+)-dependent acceleration of guanylyl cyclase, can successfully account for changes i

189 ugh H(2)S does not directly activate soluble guanylyl cyclase, it maintains a tonic inhibitory effect

190 wn cells and agonists for either adenylyl or guanylyl cyclase, it was found that PDE1B2 predominantly

191 3-a]quinoxalon-1-one, a potent inhibitor for guanylyl cyclase, or 1,2-bis(2-aminophenoxy)ethane-N,N,N

192 that release nitric oxide, stimulate soluble guanylyl cyclase, or activate cGMP-dependent protein kin

193 all kingdoms of life, e.g. in human retinal guanylyl cyclase, our findings may be significant for ma

194 3-kinase, endothelial nitric-oxide synthase, guanylyl cyclase, protein kinase G (PKG), and the mitoch

195 e cytoplasmic Ca2+ concentration, activating guanylyl cyclase, raising cyclic GMP concentration, open

196 inhibitors of NO synthase (NOS) and soluble guanylyl cyclase, respectively, abolished tadalafil indu

197 5'-cyclic monophosphate ([cGMP]i) by soluble guanylyl cyclase, resulting in fast onset and long-lasti

198 xide that retrogradely activated presynaptic guanylyl cyclase, resulting in the presynaptic expressio

199 +) in its EF-hands, stimulates photoreceptor guanylyl cyclase, RetGC1, in response to light.

200 O) receptor (alpha1.beta1 isoform of soluble guanylyl cyclase, sGC) is not known.

201 To convert BlaC into a guanylyl cyclase, we constructed a model of the nucleoti

202 yclase, which synthesizes cGMP, or a mutated guanylyl cyclase, which synthesizes cAMP.

203 e conditional expression of either wild-type guanylyl cyclase, which synthesizes cGMP, or a mutated g

204 Signaling is both soluble guanylyl cyclase- and phosphodiesterase 6-dependent but

205 ated enzymes, adenylyl cyclase-5 and retinal guanylyl cyclase-1.

206 Atrial natriuretic peptide (ANP) binds guanylyl cyclase-A (GC-A) and natriuretic peptide recept

207 t was shown that NPs, via their cGMP-forming guanylyl cyclase-A (GC-A) receptor and cGMP-dependent ki

208 Atrial natriuretic peptide (ANP) via its guanylyl cyclase-A (GC-A) receptor participates in regul

209 Guanylyl cyclase-A (GC-A) signaling, a natriuretic pepti

210 rtension decreases urine output, and second, guanylyl cyclase-A (GC-A), the primary signaling recepto

211 Guanylyl cyclase-A (GC-A), the transmembrane cGMP-produc

212 with endothelial-restricted deletion of the guanylyl cyclase-A receptor for ANP.

213 HF serums were active and generated cGMP via guanylyl cyclase-A receptors; however, the 180-minute sa

214 Atrial natriuretic peptide (ANP) binds guanylyl cyclase-A/natriuretic peptide receptor-A (GC-A/

215 Guanylyl cyclase-activating protein 1 (GCAP-1) is an EF-

216 9C or E155G mutations of the retGC modulator guanylyl cyclase-activating protein 1 (GCAP-1), which pr

217 Guanylyl cyclase-activating protein 1 (GCAP1), a myristo

218 ackground light; similar effects are seen in guanylyl cyclase-activating protein knockout (GCAPs(-/-)

219 The photoreceptor-specific proteins guanylyl cyclase-activating proteins (GCAPs) bind and re

220 ane guanylyl cyclase 1 (RetGC1) regulated by guanylyl cyclase-activating proteins (GCAPs) controls ph

221 RetGC catalytic activity and stimulation by guanylyl cyclase-activating proteins (GCAPs).

222 structure of human BNP to activate GC-A and guanylyl cyclase-B (GC-B), which is not reduced in heart

223 g 8-bromo-cGMP, as well as by the NO-soluble guanylyl cyclase-cGMP signaling inhibitor thrombospondin

224 The endogenous NO acts to stimulate guanylyl cyclase-coupled NO receptors in the axons, lead

225 ts in target cells by binding to specialized guanylyl cyclase-coupled receptors, resulting in cGMP ge

226 rough which NO generally acts is the soluble guanylyl cyclase-cyclic GMP (sGC-cGMP) pathway.

227 Activation of the guanylyl cyclase-cyclic GMP-protein-kinase-G system with

228 adiazolo-[4,3-a]quinoxalin-1-one) (a soluble guanylyl cyclase-inhibitor, Rp-8-(4-chlorophenylthio)-gu

229 NP is a critical discriminator of binding to guanylyl cyclase-linked but not clearance natriuretic pe

230 ndicating that NO-induced AMPK activation is guanylyl cyclase-mediated and calcium-dependent.

231 n of Foxp3 in MBP-primed T cells via soluble guanylyl cyclase-mediated production of cGMP.

232 but not natriuretic peptide (NP)-stimulated guanylyl cyclase.

233 ion of a competitive inhibitor of a receptor guanylyl cyclase.

234 vitro, demonstrating that it is a functional guanylyl cyclase.

235 ssion of NF-kappaB and activation of soluble guanylyl cyclase.

236 ein-coupled receptors, adenylyl cyclase, and guanylyl cyclase.

237 f cGMP in response to nitric oxide-activated guanylyl cyclase.

238 way and the subsequent activation of soluble guanylyl cyclase.

239 ndothelial nitric-oxide synthase and soluble guanylyl cyclase.

240 of NO synthase and subsequent activation of guanylyl cyclase.

241 taining the synaptic localization of soluble guanylyl cyclase.

242 ndothelial nitric oxide synthase and soluble guanylyl cyclase.

243 extent, by the direct stimulation of soluble guanylyl cyclase.

244 a multidomain, membrane-associated receptor guanylyl cyclase.

245 h, among other functions, stabilizes soluble guanylyl cyclase.

246 The guanylyl cyclase/cGMP signaling triggers opening of KATP

247 The nitric oxide-sensitive guanylyl cyclase/cGMP-dependent protein kinase type I si

248 hyperphosphorylation occurs through soluble guanylyl cyclase/guanosine 3',5'-cyclic monophosphate si

249 eted disruption of the Npr1 gene (coding for guanylyl cyclase/natriuretic peptide receptor A (NPRA))

250 rial and brain natriuretic peptides activate guanylyl cyclase/natriuretic peptide receptor-A (GC-A/NP

251 tion of retinal arterioles via activation of guanylyl cyclase; cyclooxygenase plays a relatively mino

252 her the classical, nitric oxide (NO)-soluble guanylyl-cyclase (sGC)-cGMP pathway could modulate Ca(2)

253 rect inhibitors of an NRE-localized receptor-guanylyl-cyclase, GCY-8, which synthesizes cyclic guanos

254 The effect of CORM-2 was not prevented by guanylyl-cyclase, protein kinase G, or thioredoxin inhib

255 n modification, biologically through soluble guanylyl-cyclase-dependent modulation of the MMP-9/TIMP-

256 e identified a link between impaired soluble-guanylyl-cyclase-dependent nitric oxide signalling and m

257 eight different receptor-type, transmembrane guanylyl cyclases (encoded by gcy genes), which are expr

258 Guanylyl cyclases (GCs) catalyze the conversion of GTP t

259 ions of phosphodiesterase (PDE6) and retinal guanylyl cyclases (GCs), and mutations in genes that dis

260 uses PAK to directly activate transmembrane guanylyl cyclases (GCs), leading to increased cellular c

261 Guanylyl cyclases (GCs), which synthesize the messenger

262 to the activation of receptor enzymes called guanylyl cyclases (GCs).

263 expression levels of particulate (membrane) guanylyl cyclases (pGC) and cGMP-specific phosphodiester

264 or repertoire of cilia-localized particulate guanylyl cyclases (pGC-G and pGC-A).

265 We show that AFD-specific receptor guanylyl cyclases (rGCs) are instructive for thermosensa

266 the observation that multiple receptor-type guanylyl cyclases (rGCs), encoded by the gcy genes, and

267 The two main receptors of NP, membrane-bound guanylyl cyclases A and B (GC-A and GC-B), mediate the e

268 all previously uncharacterized receptor-type guanylyl cyclases and find them to be highly biased but

269 total of 27 gcy genes encoding receptor-type guanylyl cyclases and of 7 gcy genes encoding soluble gu

270 erotrimeric G proteins but is independent of guanylyl cyclases and the previously identified cGMP-ind

271 s issue, report direct communication between guanylyl cyclases and the Rac-p21-activated kinase (PAK)

272 s, harbors a catalytic center diagnostic for guanylyl cyclases and the recombinant AtPNP-R1 is capabl

273 find that >41% (11/27) of all receptor-type guanylyl cyclases are expressed in the ASE gustatory neu

274 dely distributed across all kingdoms whereas guanylyl cyclases are generally thought to be restricted

275 l motility, through allosteric activation of guanylyl cyclases by autophosphorylated PAK.

276 ntrol of cGMP levels and that membrane-bound guanylyl cyclases can be critically modulated by other r

277 Although guanylyl cyclases have been implicated in cell migration

278 cyclases and of 7 gcy genes encoding soluble guanylyl cyclases in the complete genome sequence of C.

279 peptide receptor B (NPR-B) are transmembrane guanylyl cyclases that catalyze the synthesis of cGMP in

280 g membrane-integral and soluble adenylyl and guanylyl cyclases, are central components in a wide rang

281 naling proteins, including eucaryal receptor guanylyl cyclases, but its function remains obscure.

282 The three Drosophila atypical soluble guanylyl cyclases, Gyc-89Da, Gyc-89Db, and Gyc-88E, have

283 BPIPP inhibited stimulation of guanylyl cyclases, including types A and B and soluble i

284 rs is supported by a pair of retina-specific guanylyl cyclases, retGC1 and -2.

285 canonical 5'-3' DNA polymerases and adenylyl/guanylyl cyclases, two enzyme families known to use a tw

286 nfers Ca(2+)-dependent activation of retinal guanylyl cylcase (RetGC) during phototransduction in vis

287 MP), to Ribonuclease Sa (RNase Sa), a small, guanylyl-endoribonuclease from Streptomyces aureofaciens

288 Soluble guanylyl/guanylate cyclase (sGC) converts GTP to cGMP af

289 Soluble guanylyl/guanylate cyclase (sGC), a heme-containing hete

290 Soluble guanylyl/guanylate cyclase (sGC), the primary biological

291 I(Ca) modulation induced with intracellular guanylyl imidophosphate was also attenuated by FALI.

292 e U5 region between Src homology 3 (SH3) and guanylyl kinase-like (GK) domains were identified in rat

293 miting enzyme required for the production of guanylyl metabolites and cGMP.

294 cial case of the model in which agonists and guanylyl nucleotides interact within a complex that is b

295 allosteric interaction between agonists and guanylyl nucleotides.

296 de-ion transport stimulated by activation of guanylyl or adenylyl cyclases and suppressed STa-induced

297 ata, the first crystal structure of a small, guanylyl ribonuclease bound to 3'IMP was determined to 2

298 is, an open GTase domain for His217-mediated guanylyl transfer, and an open methylase-1 domain for SA

299 thway: (i) guanylylation of the enzyme, (ii) guanylyl-transfer to the RNA substrate, and (iii) overal

300 homologous enzymatic protein pairs, such as guanylyl versus adenylyl cyclases, lactate versus malate